COVID-19 vaccines adverse events: potential molecular mechanisms

Immunologic Research, Journal Year: 2023, Volume and Issue: 71(3), P. 356 - 372

Published: Jan. 6, 2023

Language: Английский

---

Global Burden of Vaccine-Associated Cerebrovascular Venous Sinus Thrombosis, 1968–2024: A Critical Analysis From the WHO Global Pharmacovigilance Database

Journal of Korean Medical Science, Journal Year: 2025, Volume and Issue: 40

Published: Jan. 1, 2025

Despite widespread coronavirus disease 2019 (COVID-19) vaccine use, research on the association between vaccines and cerebrovascular venous sinus thrombosis (CVST) in diverse populations is limited. This study aimed to address this gap. Data from World Health Organization pharmacovigilance database (1968-2024; total reports = 8,909,484) were used. Reporting odds ratios (RORs) information components (ICs) calculated assess each drug CVST. In total, 851 cases identified as vaccine-associated CVST, of which 527 (61.93%) occurred female patients. Only Ad5-vectored COVID-19 had highest ROR IC value with CVST (ROR, 4.78; 95% confidence interval, 4.34-5.28; IC, 2.15). The risk increased age, 45-64-years age group having an 1.35, while 65 years older a higher 2.08. findings highlight need for clinicians recognize potential risks prioritize rigorous monitoring ensure patient safety.

Language: Английский

---

Ocular Manifestations after Receiving COVID-19 Vaccine: A Systematic Review

Vaccines, Journal Year: 2021, Volume and Issue: 9(12), P. 1404 - 1404

Published: Nov. 27, 2021

The coronavirus disease 2019 (COVID-19) pandemic has had profound and lasting consequences since 2019. Although vaccines against COVID-19 have been developed approved under emergency use authorization, various adverse events also reported after vaccination. This review was undertaken to help clinicians recognize the possible manifestations systemic pathogenesis, especially those related eye, receiving A search performed on 22 August 2021 through Embase, Medline, Cochrane Library for publications ocular Two case-control studies/retrospective cohort studies, one cross-sectional study, three case series, sixteen reports, two images, seven letters were included. Ocular may appear eyelid, cornea surface, retina, uvea, nerve, vessel. occurred up forty-two days vaccination, vaccine-induced immunologic responses be responsible. incidence rate of symptoms is considerably lower in vaccinated subjects than patients, physicians should aware associations between early diagnosis treatment vision problems or life-threatening complications.

Language: Английский

---

Emergence of Post COVID-19 Vaccine Autoimmune Diseases: A Single Center Study

Infection and Drug Resistance, Journal Year: 2023, Volume and Issue: Volume 16, P. 1263 - 1278

Published: March 1, 2023

Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) became a major concern since the announcement that it is pandemic in early 2020. Vaccine trials were started November 2020, and completed rapidly due to urgency get over infection. Side effects vaccines be reported. There minor side including site of injection pain heaviness constitutional symptoms like fever which are considered minor. One rare adverse events post vaccine new onset autoimmune diseases. Methods: Data obtained from one center eastern province Saudi Arabia (King Fahd Hospital University). All patient reported occurred study period March 2021 February 2022. We identified patients presenting with diseases exclusively presentations. Results: 31 cases immune-mediated disease: 18 females (58%); 13 males (42%). Only 4 them (13%) had an background before COVID-19 vaccination. The average time between vaccination new-onset disease was 7 days. Among all our study, (22.5%) vasculitis, IgA vasculitis 5 ANCA 6 neurological (19.3%), (12.9%) systemic lupus erythematosus (SLE), 3 (9.6%) presented inflammatory arthritis, Sjogren's (3.2%). Conclusion: Our unique as first include largest number (31 patients) onsets confirmed related Covid-19 vaccines. Keywords: disease, SARS CoV-2, vaccine,

Language: Английский

---

Can COVID-19 Vaccines Induce Premature Non-Communicable Diseases: Where Are We Heading to?

Vaccines, Journal Year: 2023, Volume and Issue: 11(2), P. 208 - 208

Published: Jan. 17, 2023

According to the WHO, as of January 2023, more than 850 million cases and over 6.6 deaths from COVID-19 have been reported worldwide. Currently, death rate has reduced due decreased pathogenicity new SARS-CoV-2 variants, but major factor in rates is administration 12.8 billion vaccine doses globally. While vaccines are saving lives, serious side effects after vaccinations for several premature non-communicable diseases (NCDs). However, adverse events low number. The scientific community must investigate entire spectrum COVID-19-vaccine-induced complications so that necessary safety measures can be taken, current re-engineered avoid or minimize their effects. We describe depth severe metabolic, mental, neurological disorders; cardiovascular, renal, autoimmune diseases, reproductive health issues detected whether these causal incidental. In any case, it become clear benefits outweigh risks by a large margin. pre-existing conditions vaccinated individuals need taken into account prevention treatment events.

Language: Английский

---

Age- and Sex-Graded Data Evaluation of Vaccination Reactions after Initial Injection of the BNT162b2 mRNA Vaccine in a Local Vaccination Center in Germany

Vaccines, Journal Year: 2021, Volume and Issue: 9(8), P. 911 - 911

Published: Aug. 16, 2021

A high vaccination rate of older and particularly chronically ill people against coronavirus disease-2019 (COVID-19) is likely one the most important factors in containing pandemic. When Germany’s campaign started on December 2020, prioritization was initially carried out starting with population groups. Side effect rates 1065 individuals who had received first dose messenger ribonucleic acid (mRNA) vaccine BNT162b2 Tozinameran from BioNTech/Pfizer three weeks earlier were examined retrospectively. An age- gender-graded data analysis showed clear age gender differences regard to vaccine-related adverse effects. In 77% all over 80 years age, no local or systemic side effects reported after vaccination, whereas group up years, only 37% whole study population, 64% females 73% males The initial mRNA shows an overall low profile Particularly those extraordinarily good tolerance equally effectiveness evident. sex comparison that women suffer more often reactions. order achieve sufficient herd immunity, both gender-dependent reactions any difference maintenance immunity should be considered future strategies.

Language: Английский

---

Cardiovascular Sequelae of the COVID-19 Vaccines

Cureus, Journal Year: 2025, Volume and Issue: unknown

Published: April 10, 2025

Vaccines against COVID-19 present a key tool in lowering the morbidity, mortality, and transmission of disease, but they also strongly controversial topic. As result, adverse effects vaccine have been under scrutiny by public eye. A comprehensive summary cardiovascular (CV) vaccines is vital for clinical recognition rare events, determining health implications, creating base future research. In May 2023, search was conducted PubMed Cochrane databases to identify literature on CV complications resulting from vaccine. All articles with relevant data discussion regarding were included review. total, 4419 screened, 166 The vaccine-associated events encompassed following conditions: myocarditis, pericarditis, acute coronary syndrome, stress cardiomyopathy, hypertension, isolated tachycardia, myocardial infarction (MI) nonobstructive arteries (MINOCA), cardiac arrest, vaccine-induced thrombotic thrombocytopenia (VITT), MI, cerebral venous thrombosis (CVT), deep vein (DVT), pulmonary embolism (PE), other disorders. Among these, myocarditis thrombosis, especially VITT, emerged as most frequently cited reviewed literature. Ranges incidences recorded among articles: myocarditis: 2 17 per million, VITT: 3-10 CVST: 2.6-10 MI: 3-4 million. entail potential although at low incidence, some which exhibit notable severity. These demographic specificity vaccine-specific profiles. are uniformly nature. existing body evidence offers limited support assertion that may elevate baseline risk long term. However, available research greater than six months scarce.

Language: Английский

---

Persistence of Anti-SARS-CoV-2 Spike IgG Antibodies Following COVID-19 Vaccines

Infection and Drug Resistance, Journal Year: 2022, Volume and Issue: Volume 15, P. 4127 - 4136

Published: July 1, 2022

This study was conducted to investigate antibody immune responses induced by BNT162b2 and AZD1222 human COVID-19 vaccines in Riyadh city, Saudi Arabia.ELISA used evaluate antibodies, against the SARS-CoV-2 spike S1 protein, serum samples from 432 vaccinated individuals at six time points: pre-vaccination (baseline), post-prime, post-boost, 6-months, 1 year post-vaccination, 3 weeks post a third dose. Virus microneutralization assay confirm subset of samples.Anti-SARS-CoV-2 IgG were detected most subjects reached peak level remained high 6-month follow-up. At post-vaccine, levels low but increased significant higher than following The dose given an average 250 days after second virus confirmed neutralization activity antibodies. titres post-prime (p=0.0001) 6 months (p=0.006) previously infected individuals. An interval between prime boost, more recommended time, appeared enhance (p=0004). Moreover, younger (p=0.01).These data provide insights build on current understanding these two vaccines; support boosting for vaccines.

Language: Английский

---

SARS-CoV-2 Vaccines: Types, Working Principle, and Its Impact on Thrombosis and Gastrointestinal Disorders

Applied Biochemistry and Biotechnology, Journal Year: 2022, Volume and Issue: 195(2), P. 1541 - 1573

Published: Oct. 12, 2022

Language: Английский

---

What Happens to the Immune System after Vaccination or Recovery from COVID-19?

Life, Journal Year: 2021, Volume and Issue: 11(11), P. 1152 - 1152

Published: Oct. 29, 2021

Due to its leading role in fighting infections, the human immune system has been focus of many studies context Coronavirus disease 2019 (COVID-19). In a worldwide effort, scientific community transitioned from reporting about effects novel coronavirus on body early days pandemic exploring body's immunopathological and immunoprotecting properties that have improved treatment enabled development vaccines. The aim this review is explain what happens after recovery COVID-19 and/or vaccination against SARS-CoV-2, virus causes disease. We detail way which responds SARS-CoV-2 infection, including innate adaptive measures. Then, we describe vaccination, main types vaccines how they protect us. Further, reason why immunity infection plus appears induce stronger response compared with exposure alone. Additionally, reports some correlates protection infection. conclusion, reinforce safe important achieving herd immunity.

Language: Английский

---